Recent news on Infasurf

Preterm Infants with Respiratory Distress Syndrome: Incidence ...  -  May 7, 2007
PR Newswire (press release),Infasurf is a registered trademark of Forest Pharmaceuticals, Inc. Media contacts: Dey, LP Media Line 1-800-755-5560 ext. 8363 or Harriet Ullman Feinstein

Preterm Infants with Respiratory Distress Syndrome: Incidence ...  -  May 7, 2007
PharmaLive.com (press release),Survanta is a registered trademark of Ross Product Division, Abbott Laboratories Inc. Infasurf is a registered trademark of Forest Pharmaceuticals, Inc.

Preterm Infants With RDS -- Surfactant Replacement Therapies ...  -  May 12, 2007
Medical News Today (press release),...therapies over which Curosurf® Intratracheal Suspension showed a nearly 20% mortality advantage are Survanta® (beractant) and Infasurf® (calfactant).

Lung Treatments For Premature Babies Assessed By Study  -  May 12, 2007
Medical News Today (press release),Premier Inc. 4953 got poractant alfa, marketed as Curosurf®; 12653 got beractant marketed as Survanta®; and 7277 got calfactant, marketed as Infasurf®.

Surfactant replacement therapies improve neonatal survival in ...  -  May 9, 2007
News-Medical.net,...therapies over which Curosurf, Intratracheal Suspension showed a nearly 20% mortality advantage are Survanta, (beractant) and Infasurf, (calfactant).

Study compares three natural surfactants used to treat babies with ...  -  May 9, 2007
News-Medical.net,Premier Inc. 4953 got poractant alfa, marketed as Curosurf; 12653 got beractant marketed as Survanta; and 7277 got calfactant, marketed as Infasurf".

Lung Treatments For Premature Babies Under Study  -  May 7, 2007
Science Daily (press release)...and 7277 got calfactant, marketed as Infasurf®. Results are being presented May 7 during the Pediatric Academic Societies Annual Meeting in Toronto.

Preterm Infants with Respiratory Distress Syndrome: Incidence ...  -  May 7, 2007
Earthtimes.org...nearly 20% mortality advantage are Survanta(R) (beractant) and Infasurf(R) (calfactant). Full disclosure of the data are being held pending publication.

Recordati SpA: 2006 ACCOUNTS APPROVED BY THE BOARD. DIVIDEND ...  -  Mar 6, 2007
SYS-CON Media,In June an exclusive license agreement was signed with Ony Inc., a US drug development company, for the marketing and sale in Europe of Infasurf®,

Recordati SpA : une croissance internationale stable a permis l' ...  Oct 30, 2006
Rachat des droits de marketing et de ventes de Corifeo(R)(lercanidipine) en Allemagne. • Licence d'utilisation du produit obtenue pour Infasurf(R). ... -TF1, Recordati SpA: Revenues and profitability increase in the first ...  Oct 30, 2006
June Recordati entered into an exclusive license agreement with Ony Inc., a US drug development company, for the marketing and sale in Europe of Infasurf(R), a ... -TF1, RECORDATI achète l'activité pharmaceutique de Jaba au Portugal  Jul 28, 2006
...a treatment for the symptoms of benign prostatic hyperplasia), stannsoporfin (indicated for the treatment of neonatal hyperbilirubinemia), Infasurf(R) (for the ... -TF1

Recordati signs exclusive licence to sell Ony's Infasurf neonatal ...  Jun 23, 2006
MILAN (AFX) - Recordati SpA said it has signed an exclusive licence with US biotech company Ony Inc to sell in Europe Ony's Infasurf treatment for respiratory ... -Forbes

Recordati Licenses Infasurf from Ony Inc. (USA) for Europe  Jun 23, 2006
...that it has entered into an exclusive license agreement with Ony Inc., a US drug development company, for the marketing and sale of Infasurf®, a calf derived ... -PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional